Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Exclusion Criteria

• •Patients with leptomeningeal metastases documented by MRI or cerebrospinal fluid (CSF).
• •Significant intratumoral or peritumoral hemorrhage
• •Brain metastases within 5 mm of the optic chiasm or optic nerve
• •Brainstem metastases
• •Gastrointestinal disorders with diarrhea as a major symptom
• •Clinically significant or uncontrolled cardiac disease (NYHA functional classification of 3 or 4)
• •Pre-existing interstitial lung disease or pneumonitis
• •Unable to undergo brain MRI
• •HIV or Hepatitis B or C
• •Prior treatments must be resolved to an asymptomatic state at time of enrollment
• •Medical conditions that could cause safety risks
• •Currently receiving investigational cancer therapy.
• •Mean QT interval corrected heart rate (QTc)≥470ms calculated from 3 EKGs
• •Left Ventricular Ejection Fraction (LVEF) ≤ 50%
• •Use of strong CYP3A inhibitors
• •Use of strong CYP3A4 inducers
• •Use of potent CYP2C8 inhibitors
• •Hypersensitivity to osimertinib or any of its ingredients
• •corneal ulceration
• •pregnant or breast-feeding